Drug Discovery, NAMs & Biomedical AI | DENVIS & ADMETrix Platforms | Greek SME DeepLab | Technical Partner

ORGANIZATION: DeepLab (Greek SME) – Deep-Tech AI/ML for Drug Discovery & Biomedical Research

WHO WE ARE:

DeepLab is a Greek SME specializing in advanced machine learning for drug discovery and biomedical research. We combine production-ready platforms with custom-tailored solutions—all designed with built-in interpretability for regulatory acceptance. 15+ years research, 8+ years industrial ML at scale, EU project experience (multilab.eu WP leadership).

PRODUCTION PLATFORMS:

- DENVIS – Ultra-fast virtual screening (1B+ molecules, 0.314ms/compound, JEDI Grand Challenge top-20/138)

- ADMETrix – De novo generation with real-time ADMET optimization (27 properties, DILI risk 93%→7%, first REINVENT + ADMET AI integration)

CORE CAPABILITIES:

- In silico NAMs: Computational alternatives to animal testing for early drug development

- Multi-omics integration: Genomics, transcriptomics, proteomics, metabolomics fusion

- Biomarker discovery & patient stratification algorithms

- Interpretable ML with uncertainty quantification for regulatory-grade evidence

- Graph Neural Networks for biological network analysis

PUBLISHED RESEARCH:

Deep-ID (interpretable precision medicine), pCCI (cell-cell interactions, IEEE BIBM 2023), Mask-cscGAN (synthetic data, IEEE Big Data 2023). All methodologies are indicative and are to be advanced and adapted to partner-specific data and requirements.

TARGET CALLS:

- HORIZON-HLTH-2026-01-TOOL-03 (NAMs integration) – EXCELLENT FIT

- HORIZON-HLTH-2026-01-DISEASE-03 (Post-infection conditions)

- HORIZON-HLTH-2026-01-DISEASE-11 (Sex/gender CVD mechanisms)

- HORIZON-HLTH-2026-01-IND-03 (Regulatory science for health tech)

CONSORTIUM CONTRIBUTION:

Lead AI/ML work packages. Deploy production NAM platforms. Develop custom multi-omics pipelines and interpretable predictive models. Generate regulatory evidence packages.

KEYWORDS:

drug discovery, virtual screening, DENVIS, ADMETrix, NAMs, ADMET, multi-omics, biomarker discovery, interpretable ML, explainable AI, precision medicine, Greek SME, deep learning

WHY US:

Deep-tech ML, not buzzword AI—we build the engine, not just the wrapper. Research rigor meets industrial scale. Custom solutions with built-in explainability.

SEEKING:

NAM coordinators, university hospitals with cohorts, pharma partners with validation datasets, regulatory science institutes.

CONTACT: Persa Frantzi, Vassilis Pitsikalis; proposals@deeplab.ai, deeplab.ai